By Michael Nevradakis, Ph.D. | The Defender | January 17, 2023 Moderna raked in significant earnings in 2022, based on $18.4 billion in sales of its mRNA COVID-19 vaccine — the company’s one and only product on the market. But in a Jan. 9 update on the company’s “industry-leading mRNA pipeline,” Moderna told investors it is developing multiple […]
Source